Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - paracetamol, quantity: 500 mg; pseudoephedrine hydrochloride, quantity: 30 mg; chlorphenamine maleate, quantity: 2 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; magnesium stearate; erythrosine; povidone; microcrystalline cellulose; colloidal anhydrous silica; maize starch - temporary symptomatic relief of rhinorrhoea, nasal congestion, headache, myalgia and fever in patient aged 12 years and over. the night tablets also provide temporary symptomatic relief from sneezing and itchy watery eyes.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - codeine phosphate hemihydrate, quantity: 6 mg; paracetamol, quantity: 500 mg; pseudoephedrine hydrochloride, quantity: 30 mg - tablet, uncoated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; maize starch; sodium starch glycollate; microcrystalline cellulose; povidone - temporary symptomatic relief of rhinorrhoea, nasal congestion, headache, myalgia and fever in patient aged 12 years and over.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose; lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000 - early breast cancer. adjuvant treatment of early breast cancer in postmenopausal women with oestrogen/progesterone receptor positive disease.,advanced breast cancer. first line treatment of advanced breast cancer in postmenopausal women with oestrogen/ progesterone receptor positive disease. treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with oestrogen receptor negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; maize starch; pregelatinised maize starch; lactose monohydrate; magnesium stearate; povidone - inoperable prostatic carcinoma. to suppress 'flare' with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 10 mg - tablet, uncoated - excipient ingredients: maize starch; purified talc; magnesium stearate; povidone; colloidal anhydrous silica; sodium lauryl sulfate; sodium starch glycollate - temporary relief of acute moderate pain and fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 15 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; maize starch; sodium lauryl sulfate; povidone; purified talc; magnesium stearate; colloidal anhydrous silica; hyprolose; stearic acid - temporary relief of acute moderate pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; povidone; colloidal anhydrous silica; lactose monohydrate; pregelatinised maize starch - women: moderately severe to severe signs of androgenisation. moderately severe/severe forms of hirsutism. moderately severe/severe androgen-dependent loss of scalp hair (moderately severe/severe andogenetic alopecia). moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenisation. cyproterone acetate inhibits the influence of male sex hormones, which are also produced by the female. it is thus possible to treat diseases in women caused either by increases production of androgens or a particular sensitivity to these hormones. hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment. if meditab cyproterone is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of child bearing potential, pregnancy must be excluded at the commencement of treatment and ethinyl oestradiol taken as well to ensure contraception. this also promotes regular menstruation.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 129.08 mg (equivalent: bosentan, qty 125 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - bosentan monohydrate, quantity: 64.5 mg (equivalent: bosentan, qty 62.5 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type b; povidone; pregelatinised maize starch; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; triacetin; iron oxide yellow; iron oxide red; purified water; ethylcellulose; cetyl alcohol; hydrogen peroxide; sodium lauryl sulfate; octamethylcyclotetrasiloxane; silica dimethicone silylate; dimeticone 5000; cyclomethicone - bosentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - familial pulmonary arterial hypertension - pulmonary arterial hypertension associated with scleroderma or - pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who functional class ii, iii or iv symptoms.